| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Cancer Research Institute, University of California San Francisco, San Francisco, California and 2 Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, Tokyo, Japan
Requests for reprints: Frank McCormick, University of California San Francisco, Cancer Research Institute, 2340 Sutter Street, N-331, UCSF Box 0128, San Francisco, CA 94115. Phone: 415-502-1710; Fax: 415-502-1712; E-mail: mccormick{at}cc.ucsf.edu.
The phosphatidylinositol 3'-kinase (PI3K) pathway is activated in many human cancers. In addition to inactivation of the PTEN tumor suppressor gene, mutations or amplifications of the catalytic subunit 
of PI3K (PIK3CA) have been reported. However, the coexistence of mutations in these two genes seems exceedingly rare. As PTEN mutations occur at high frequency in endometrial carcinoma, we screened 66 primary endometrial carcinomas for mutations in the helical and catalytic domains of PIK3CA. We identified a total of 24 (36%) mutations in this gene and coexistence of PIK3CA/PTEN mutations at high frequency (26%). PIK3CA mutations were more common in tumors with PTEN mutations (17 of 37, 46%) compared with those without PTEN mutations (7 of 29, 24%). Array comparative genomic hybridization detected 3q24-qter amplification, which covers the PIK3CA gene (3q26.3), in one of nine tumors. Knocking down PTEN expression in the HEC-1B cell line, which possesses both K-Ras and PIK3CA mutations, further enhances phosphorylation of Akt (Ser473), indicating that double mutation of PIK3CA and PTEN has an additive effect on PI3K activation. Our data suggest that the PI3K pathway is extensively activated in endometrial carcinomas, and that combination of PIK3CA/PTEN alterations might play an important role in development of these tumors.
This article has been cited by other articles:
|
|
 |
|
  S. Wee, D. Wiederschain, S.-M. Maira, A. Loo, C. Miller, R. deBeaumont, F. Stegmeier, Y.-M. Yao, and C. Lengauer PTEN-deficient cancers depend on PIK3CB PNAS, September 2, 2008; 105(35): 13057 - 13062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Perrone, A. Lampis, M. Orsenigo, M. Di Bartolomeo, A. Gevorgyan, M. Losa, M. Frattini, C. Riva, S. Andreola, E. Bajetta, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Ann. Onc., July 31, 2008; (2008) mdn541v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. E. Velculescu Defining the blueprint of the cancer genome Carcinogenesis, June 1, 2008; 29(6): 1087 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. H. Lu, W. Wu, B. Dave, B. M. Slomovitz, T. W. Burke, M. F. Munsell, R. R. Broaddus, and C. L. Walker Loss of Tuberous Sclerosis Complex-2 Function and Activation of Mammalian Target of Rapamycin Signaling in Endometrial Carcinoma Clin. Cancer Res., May 1, 2008; 14(9): 2543 - 2550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Opitz, A. Soltermann, M. Abaecherli, M. Hinterberger, N. Probst-Hensch, R. Stahel, H. Moch, and W. Weder PTEN expression is a strong predictor of survival in mesothelioma patients Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 502 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Andres-Pons, I. Rodriguez-Escudero, A. Gil, A. Blanco, A. Vega, M. Molina, R. Pulido, and V. J. Cid In vivo Functional Analysis of the Counterbalance of Hyperactive Phosphatidylinositol 3-Kinase p110 Catalytic Oncoproteins by the Tumor Suppressor PTEN Cancer Res., October 15, 2007; 67(20): 9731 - 9739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Perez-Tenorio, L. Alkhori, B. Olsson, M. A. Waltersson, B. Nordenskjold, L. E. Rutqvist, L. Skoog, and O. Stal PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer Clin. Cancer Res., June 15, 2007; 13(12): 3577 - 3584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Saal, P. Johansson, K. Holm, S. K. Gruvberger-Saal, Q.-B. She, M. Maurer, S. Koujak, A. A. Ferrando, P. Malmstrom, L. Memeo, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity PNAS, May 1, 2007; 104(18): 7564 - 7569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Moreno-Bueno, P. J. Fernandez-Marcos, M. Collado, M. J. Tendero, S. M. Rodriguez-Pinilla, I. Garcia-Cao, D. Hardisson, M. T. Diaz-Meco, J. Moscat, M. Serrano, et al. Inactivation of the Candidate Tumor Suppressor Par-4 in Endometrial Cancer Cancer Res., March 1, 2007; 67(5): 1927 - 1934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Hayes, H. Wang, R. Espinal-Witter, W. Douglas, G. J. Solomon, S. J. Baker, and L. H. Ellenson PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia. Clin. Cancer Res., October 15, 2006; 12(20): 5932 - 5935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Hecht and G. L. Mutter Molecular and Pathologic Aspects of Endometrial Carcinogenesis J. Clin. Oncol., October 10, 2006; 24(29): 4783 - 4791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Gallia, V. Rand, I-M. Siu, C. G. Eberhart, C. D. James, S. K.N. Marie, S. M. Oba-Shinjo, C. G. Carlotti, O. L. Caballero, A. J.G. Simpson, et al. PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme Mol. Cancer Res., October 1, 2006; 4(10): 709 - 714. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
